A biotech tests Wall Street's roiled waters and comes away with a $75M IPO haul
Imara didn’t have the prettiest pricing moment for its IPO this week, but it did make it out onto the market — braving a Wall …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
